Dr. Ola Landgren obtained his M.D. and Ph.D., completed his specialist training in hematology, and served as an attending physician at the Karolinska Institute in Stockholm, Sweden. He serves as a Senior Investigator and attending physician at the National Cancer Institute (NCI), National Institutes of Health (NIH) in Bethesda, MD. As Chief of the Multiple Myeloma Section, he is responsible for the biological discovery program focusing on myeloma and its precursor states and for the program focusing on novel drug development for myeloma and its high risk precursor disease. Dr. Landgren has published over 170 scientific papers, is a member of several editorial boards, and scientific societies. He frequently speaks at national and international meetings. Dr. Landgren serves as the Chair for the NCI Scientific Review Committee, the central scientific review section for all new clinical trials developed and launched at the Medical Oncology Branch and Affiliated Branches at NCI.